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It was not that long ago that it was suggested that mastectomy might
not be necessary to treat breast cancer and that lumpectomy and whole
breast radiation could be a suitable alternative. When Dr. Fisher and the
NSABP first proposed doing a randomized trial of lumpectomy,
lumpectomy, and radiation or mastectomy [1], it was met with
tremendous skepticism. Many surgeons were quite vocal in their
concern regarding local recurrence and the impact it might have on
survival. Nevertheless, the trial took place, and today the majority of
breast cancer patients in the United States avoid mastectomy. This sort
of skepticism is not unusual in surgery. The idea that the gallbladder
could be removed via a small umbilical incision, using laparascopic
technology, was considered outlandish, and would fade away once an
inordinate number of common bile duct injuries were reported. The
concept of not diverting the colon after penetrating trauma, of the non-
operative management of splenic injuries, of treating vascular disease
with stents rather than surgery, or the suggestion of staging melanoma
or breast cancer by removing just one or two lymph nodes rather than a
complete lymph node dissection are all examples of changes in
surgical paradigm that met tremendous resistance when first proposed
but became standard surgical practice.
Today, a similar surgical reluctance surrounds the idea of in situ
ablation for the treatment of breast cancer, and specifically the use of
cryoablation. Cryoablation involves the introduction of a cryoprobe
into the center of a tumor under ultrasound guidance in order to freeze
the tissue to temperatures between 160 and 1908C. Several small
studies have now demonstrated the safety, feasibility, efficacy, and
limitations of cryoablation in the treatment of breast cancer [2–5].
Data from these studies, most of which involve cryoablation followed
by standard surgical resection, are being used to design larger
studies pursuing the ultimate goal of cryoablation; an alternative to
lumpectomy. However, the idea of ablating a tumor and leaving it in
place, without the opportunity for histological evaluation of the
margins, seems like surgical heresy to many surgical oncologists. As
with the shift from mastectomy to breast conservation, there is
significant concern regarding leaving untreated disease, particularly in
situ disease, leading to an unacceptable local recurrence rate. These are
highly legitimate concerns, and certainly no one is advocating the
immediate introduction of cryoablation as an alternative to lumpect-
omy. However, there are many potential advantages to cryoablation
over lumpectomy that warrant its further investigation.
Cryoablation is technically simple and extremely safe, with mini-
mal discomfort or side effects for the patient [6]. Successful cryoabla-
tion requires only moderate proficiency with ultrasound, which is
rapidly becoming an essential component of any breast practice
[7]. After percutaneous ultrasound guided placement of the probe
within the center of the tumor, the procedure involves monitoring the
formation of the iceball and occasionally injecting saline between the
iceball and the skin to prevent thermal damage. After two freeze-thaw
cycles, the probe is removed and a bandage placed over the incision.
Because the freezing procedure itself anesthetizes the breast tissue, no
local or regional anesthesia is required past the placement of the probe.
Patients report minimal discomfort or use of narcotic pain medications
afterwards [4]. Compared with lumpectomy, cryoablation would
represent a tremendous reduction in the cost and morbidity of breast
cancer treatment.
More importantly to the patient, the cosmesis achieved with cryoabla-
tion is superior to that obtained with lumpectomy. Even for small tumors,
lumpectomy and radiation can be associated with not only a scar, but
volume loss and asymmetry, retraction and concavity. Cryoablation leaves
a scar no bigger than that of a percutaneous core biopsy. By leaving the
frozen tissue in situ for resorption by the body, the breast maintains its
natural size and shape, with no resultant volume loss or deformity. The
cosmetic appeal of cryoablation is well known both to dermatologists, who
use it routinely for the ablation of skin cancers, and breast surgeons, who
use cryoablation for the treatment of fibroadenomas. Several studies have
now demonstrated the outstanding safety, efficacy, cosmetic outcome, and
patient satisfaction with cryoablation as a treatment of benign breast
disease [8–10].
Another unique feature of cryoablation that may be exploited is the
immunologic response initiated by the absorption of the frozen tissue.
The uptake of intact tumor antigens by antigen presenting cells and the
release of proinflammatory cytokines, both of which are hallmarks of
cryoablation, represent the perfect equation for initiating a tumor-
specific immune response. The ‘‘cryoimmunologic’’ response has been
well documented in both pre-clinical and clinical investigations
[3,11,12]. The use of immunotherapy in the treatment of breast cancer
is fraught with challenges, and cryoablation alone, or more likely in
combination with immune adjuncts, may overcome these obstacles
[13,14]. It is feasible that this aspect may elevate cryoablation beyond
lumpectomy in terms of local or distant recurrence. This may also
further support the role of cryoablation in other aspects of breast cancer
therapy, such as the treatment of primary tumors in the face of stage IV
disease, the eradication of chest wall recurrences, or the ablation of
metastatic foci as an alternative to metastatectomy.
Of course, none of this potential means anything if cryoablation of
primary malignant disease is associated with an unacceptably high rate
of local recurrence. The importance of local recurrence in the
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management of breast cancer, and its potential impact on survival, is
increasingly clear [15–17]. But the present limitations or concerns
regarding cryoablation do not argue against further evaluation, but
rather the importance of well-designed clinical trials to optimize
patient selection and identify patients who may not have had a
complete response. Initial trials clearly demonstrate that patients with
lobular carcinoma or an extensive intraductal component (EIC) are
poor candidates due to the discordance of imaging findings with
pathologic findings [4]. Tumor size is also an issue with present
technologies, although this may be easily overcome with modifications
to the equipment. The biggest objection to cryoablation, and by far the
largest obstacle to be overcome, is the fact that with today’s imaging,
even the patient with a small, ductal carcinoma, who seems ideal for
cryoablation, could harbor occult disease outside the iceball. Critics
would argue that this disease would be missed by in situ ablation but
recognized by histological analysis of the lumpectomy specimen
(although the local recurrence rate after lumpectomy alone, even with
negative margins, clearly demonstrates that even pathology misses
much of this disease). However, this is not an indictment of cryoabla-
tion, but of our present ability to image invasive and in situ disease of
the breast.
Our current imaging capabilities are the limiting factor with
cryoablation, but as imaging technologies improve, so too will our
ability to select appropriate patients and identify residual disease after
treatment. Magnetic resonance imaging (MRI) may already be the key
to this [5,18]. Pre-treatment MRI may select out patients with tumor
extension beyond the predicted iceball, and post-treatment MRI (with
or without biopsies from the periphery of the ablation zone) may
identify patients who have residual disease, separating those that can
proceed to radiation from those who should have lumpectomy. The role
of MRI and cryoablation is the subject of ongoing and planned clinical
trials. However, even if MRI is not the answer, it is only a matter
of time before more sophisticated imaging can identify patient
populations for whom in situ ablation is appropriate.
In the movie The Matrix, as the protagonist Neo is forced in front of
an oncoming train, he is asked by his would-be killer, ‘‘Do you hear
that sound, Mr. Anderson? That is the sound of inevitability.’’ Although
Neo obviously escapes, surgeons have not always been that fortunate.
There are several examples where surgeons failed to embrace
promising new technologies, only to see the management of ‘‘surgical’’
diseases lost to other fields. One needs look no further than the fields of
cardiac or vascular surgery. The shift frommastectomy to lumpectomy,
from node dissection to sentinel node biopsy, from whole breast
radiation to partial breast radiation, and from excisional biopsy to
percutaneous biopsy all demonstrate the direction breast cancer
management is moving; equally effective but less drastic forms of
treatment. Cryoablation of breast disease is the next logical step.
Cryoablation of primary prostate or renal cell carcinoma is already
accepted therapy. In breast cancer, almost all essential information can
be obtained from a core biopsy, including genomic analysis, precluding
the need for surgical resection for prognostic information. Widespread
screening has already greatly reduced the median size of breast tumors
and it is predicted that soon over half of all new breast cancers will be
less than 1 cm, ideal candidates for cryoablation. Further improve-
ments in both cryoablative and breast imaging technologies will only
expand the applicability of this approach. If we fail to establish
ourselves as leaders in this field, and guide the clinical trials and basic
science research that establish its efficacy and proper implementation,
then radiologists certainly will. To avoid being left behind in the
management of another ‘‘surgical disease,’’ surgeons should embrace
this new technology, and not give it the cold shoulder.
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